Research in veterinary science 135 412-415 2020年10月 [査読有り]
Canine squamous cell carcinoma (SCC) is difficult to treat if local therapy is not feasible. Recently, survivin inhibitor YM155 was shown to have growth inhibitory activity on high-survivin-expressing canine SCC cell lines HAPPY and SQ4. Here, the...
Regulatory T cells (Tregs) can be targeted in cancer immunotherapy. A previous study has shown that the chemokine CCL17 and the receptor CCR4 play a role in Treg recruitment in canine urothelial carcinoma. Here, we describe the association of tumo...
Veterinary and comparative oncology 18(2) 161-168 2020年6月 [査読有り]
Some canine cases of histiocytic sarcoma (HS) carry an activating mutation in the src homology two domain-containing phosphatase 2 (SHP2) encoded by PTPN11. SHP099 is an allosteric inhibitor of SHP2 that stabilizes SHP2 in a folded, auto-inhibited...
BMC veterinary research 16(1) 64-64 2020年2月 [査読有り]
BACKGROUND: Gain-of-function mutations in KIT are driver events of oncogenesis in mast cell tumours (MCTs) affecting companion animals. Somatic mutations of KIT determine the constitutive activation of the tyrosine kinase receptor leading to a wor...
Sena Kurita   Ryo Miyamoto   Hiroyuki Tani   Masato Kobayashi   Takashi Sasaki   Kyoichi Tamura   Makoto Bonkobara   
Journal of veterinary pharmacology and therapeutics 42(6) 673-681 2019年11月 [査読有り]
One of the potential mechanisms underlying acquired resistance to toceranib in canine mast cell tumor (MCT) is the emergence of a secondary mutation in the KIT gene. Here, genetic alterations of KIT during clonal expansion and subsequent acquisiti...